Compounding does not mean FDA approval

What compounding means

A pharmacist or physician can make a medicine to fit a need that a finished drug cannot meet. A registered compounding facility can also make medicines. This work is called compounding. FDA gives examples such as a person who cannot use a dye or swallow a tablet.

That distinction applies to the medicine itself. The September 2026 record says FDA does not review compounded drugs before marketing for safety, quality, or effectiveness. A familiar ingredient name and a polished site do not change that status.

Ask for the proposed medicine in writing. Include its ingredient, form, the reason for the change, and the actual pharmacy or facility responsible for making it. Keep the medical reason separate from the quoted price. They answer different questions.

Registration does not approve the product

In the September 2026 federal framework, a section 503A pharmacy generally makes the drug for a named person on a valid prescription, while meeting the law’s other conditions. Section 503B is another part of that law: it covers facilities making sterile medicines in batches, often for clinics or hospitals, and choosing to register with FDA. These are called outsourcing facilities. They can make batches without prescriptions naming each person who will receive the medicine. Sterile means free of living germs.

Making a batch and dispensing a prescription medicine to you are different steps. The September 2026 federal rule still requires a valid prescription when a prescription drug is dispensed to a person.

For larger registered facilities, federal factory rules apply. FDA gives higher inspection priority to facilities it considers more likely to have problems. Ask when the facility was last inspected and what the findings were. State pharmacy boards handle everyday oversight of ordinary pharmacies. Those pharmacies still have quality rules to follow.

The facility chooses to register. In the September 2026 record, that choice does not gain FDA approval for the place or its drugs. How the drug is made remains a separate question.

Ask about the ingredient’s actual position

A pharmacy cannot choose any raw ingredient it likes. The September 2026 record describes legal conditions for ingredients, not tests on a batch of medicine. A 503A pharmacy must follow the published drug-quality standard that applies to the ingredient, if one exists. Where no standard applies, an approved medicine must contain the ingredient. If that does not apply either, it must appear on FDA’s official list for 503A compounding.

On the FDA safety page current as of April 22, 2026, BPC-157, CJC-1295, and several other peptides appear under nominations that were withdrawn. To nominate an ingredient is to ask for it to be considered. The agency retains its safety concerns beside those entries and gives no individual withdrawal dates.

A withdrawn request does not put the ingredient on FDA’s list. It gives no FDA approval. A separate draft policy announced October 30, 2026 comes from the Department of Health and Human Services, or HHS. For state-licensed pharmacies and physicians, HHS said it plans to hold off on enforcement when every policy condition is met. That applies to compounding semax, KPV, BPC-157, epitalon, TB-500, or MOTS-c for an individual patient’s prescription. The draft covers single-ingredient preparations, excluding blends and section 503B outsourcing facilities. It is nonbinding and gives no FDA approval; the November 3, 2026 record still places none of these six on FDA’s 503A bulks list.

Ask the prescriber to identify the specific basis for the proposed medicine, rather than repeat a broad claim that compounded medicines are available. If the answer relies on a changed list, ask which list, which entry, and what date. A clear explanation names the actual record and its limits. It does not require the reader to infer permission from a headline.

• What medical need is the preparation meant to address?
• Who makes it, and which public record identifies that facility?
• Which ingredient rule applies to this preparation?